How low is the bar for success16 Jan 2021 13:12
Recent findings on the REMAP-CAP study were published on Tocilizumab about a week ago .
In that study , Mortality was 28% , against the control group at 35% .
It was issued an EUA and added to the NHS therapies list .
800 approx patients
350 on Tocilizumab - of which 98 died ( 28% )
45 on sarilumab of which 10 died (22%)
397 on control of which 142 died ( 35% )
So Tocilizumab was approx 20% more effective than Placebo . And that was deemed successful enough to get an EUA .
Phase 2 for SNG showed approx 80% improvement compared to Placebo - I know we aren't talking Mortality here , so not so black and white , but even if Phase3 for SNG was even half as effective as phase 2 , even a third , then would it still be classed as a success ?
Percentage wise , the bar is set pretty low in order to be classed a successful trial .
Someone may be able to help clarify that for me , as I know they have changed the primary end points somewhat , but it still looks like a very large open goal .
I need to re-read the blurb on that latest RNS regarding the endpoints , but what I'm trying to say is that other drugs seem to get the green light from what look like fairly mediocre results .